Paul Cannell - Concepedia

Author

Paul Cannell

Also Known As

P Cannell, P K Cannell, P. Cannell, P.K. Cannell, PAUL CANNELL, PAUL K. CANNELL, Paul Cannell, Paul K. Cannell, Paul Kenneth Cannell, R Western

106

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Royal Perth Hospital The Alfred Hospital Peter MacCallum Cancer Centre Amgen (United States)The University of Western Australia

About

Paul Cannell is an author at Royal Perth Hospital specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	558
2	Health Sciences	2	2	27
3	Cellular Therapies	2	2	134
4	Biochemistry	1	1	30
5	Emergency Medicine	1	1	86

Paul Cannell

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety Wolfgang Hiddemann, Anna Maria Barbui, Miguel Canales, Journal of Clinical Oncology	2018	226
A pilot randomized trial comparing CD34‐selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis John J. Moore, Peter Brooks, Sam Milliken, Arthritis & Rheumatism	2002	163
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. John A. Snowden, Jakob Passweg, John J. Moore, PubMed	2004	163
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial Judith Trotman, Sally F. Barrington, David Belada, The Lancet Oncology Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma	2018	152
Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study Richard Herrmann, Marian Sturm, Kathryn Shaw, International Journal of Hematology Regenerative MedicineCell TherapyTransplantationImmunotherapyMedicine	2011	97
When the safety net of treatment has been removed: Patients’ unmet needs at the completion of treatment for haematological malignancies Elizabeth Lobb, David Joske, Phyllis Butow, Patient Education and Counseling Surgical OncologySafety NetMedicineCancer ManagementHematology	2009	86
Allogeneic Hematopoietic Stem Cell Transplantation Recipients Have Defects of Both Switched and IgM Memory B Cells Lloyd D’Orsogna, Matthew P.F. Wright, Rom G. Krueger, Biology of Blood and Marrow Transplantation	2009	78
Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response Letizia Foroni, LA Coyle, Mary Papaioannou, Leukemia Hematological MalignancyLymphoid NeoplasiaOncologyMedicineMixed-phenotype Acute Leukemia	1997	75
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results Simon J. Harrison, Paul N. Mainwaring, Timothy Price, Clinical Cancer Research	2016	71
Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM) Paul G. Richardson, Andrew Spencer, Paul Cannell, Blood	2011	64

Page 1